Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

J&J, Vanderbilt U. partner in schizophrenia

Executive Summary

In a three-year collaboration, Johnson & Johnson's Janssen Pharmaceutica NV unit will partner with Vanderbilt University to discover and develop new schizophrenia drugs. Vanderbilt will receive an up-front payment and committed research funding totaling $10mm, plus sales royalties, and reportedly could also get up to $100mm more in research milestones.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies